Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript

Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...
Medscape

Important Long-COVID Lessons From AIDS Researchers

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
The Lancet

Seema Sahay—linking behavioural science and HIV research

Today, Seema Sahay is Head of Division of Social Behavioural Research at the Indian Council of Medical Research, National Institute of Translational Virology & AIDS Research (NARI), Pune, India.
The Lancet

Deniz Gökengin—responding to HIV/AIDS in Türkiye

Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...
Jacobs School of Medicine and Biomedical Sciences - University at Buffalo

Mapping Strategies for Preventing HIV in Nigeria

A Jacobs School of Medicine and Biomedical Sciences faculty member is senior author on a newly published study on the public health challenges of HIV in Nigeria.
Billy Penn

“Not a ‘scale back,’ this is a dismantling of our program”: HIV funding cuts impact vulnerable communities

Organizations that provide services like HIV education and living recommendations are being forced to cut programming after ...

Eswatini is the first African country to get twice-yearly HIV prevention shot

The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly ...
Medical Dialogues

Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3 trial

Gilead Sciences has announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who ...